Hall GD - Search Results

1

Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity.

Wilson EB, El-Jawhari JJ, Neilson AL, Hall GD, Melcher AA, Meade JL, Cook GP. Wilson EB, et al. Among authors: hall gd. PLoS One. 2011;6(9):e22842. doi: 10.1371/journal.pone.0022842. Epub 2011 Sep 6. PLoS One. 2011. PMID: 21909397 Free PMC article.

2

Treg Depletion-enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic Virus.

Kottke T, Galivo F, Wongthida P, Maria Diaz R, Thompson J, Jevremovic D, Barber GN, Hall G, Chester J, Selby P, Harrington K, Melcher A, Vile RG. Kottke T, et al. Mol Ther. 2008 Jul;16(7):1217-1226. doi: 10.1038/mt.2008.83. Epub 2016 Dec 8. Mol Ther. 2008. PMID: 28178481

3

Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus.

Kottke T, Galivo F, Wongthida P, Diaz RM, Thompson J, Jevremovic D, Barber GN, Hall G, Chester J, Selby P, Harrington K, Melcher A, Vile RG. Kottke T, et al. Mol Ther. 2008 Jul;16(7):1217-26. doi: 10.1038/mt.2008.83. Epub 2008 Apr 22. Mol Ther. 2008. PMID: 18431359 Free PMC article.

4

Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.

Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ. Karapanagiotou EM, et al. Among authors: hall gd. Clin Cancer Res. 2012 Apr 1;18(7):2080-9. doi: 10.1158/1078-0432.CCR-11-2181. Epub 2012 Feb 7. Clin Cancer Res. 2012. PMID: 22316603 Free PMC article. Clinical Trial.

5

Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.

Kottke T, Hall G, Pulido J, Diaz RM, Thompson J, Chong H, Selby P, Coffey M, Pandha H, Chester J, Melcher A, Harrington K, Vile R. Kottke T, et al. J Clin Invest. 2010 May;120(5):1551-60. doi: 10.1172/JCI41431. Epub 2010 Apr 1. J Clin Invest. 2010. PMID: 20364090 Free PMC article.

6

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.

Oza AM, Matulonis UA, Alvarez Secord A, Nemunaitis J, Roman LD, Blagden SP, Banerjee S, McGuire WP, Ghamande S, Birrer MJ, Fleming GF, Markham MJ, Hirte HW, Provencher DM, Basu B, Kristeleit R, Armstrong DK, Schwartz B, Braly P, Hall GD, Nephew KP, Jueliger S, Oganesian A, Naim S, Hao Y, Keer H, Azab M, Matei D. Oza AM, et al. Among authors: hall gd. Clin Cancer Res. 2020 Mar 1;26(5):1009-1016. doi: 10.1158/1078-0432.CCR-19-1638. Epub 2019 Dec 12. Clin Cancer Res. 2020. PMID: 31831561 Free PMC article. Clinical Trial.

7

Systemic chemotherapy for patients with bladder cancer--current controversies and future directions.

Chester JD, Hall GD, Forster M, Protheroe AS. Chester JD, et al. Among authors: hall gd. Cancer Treat Rev. 2004 Jun;30(4):343-58. doi: 10.1016/j.ctrv.2003.12.005. Cancer Treat Rev. 2004. PMID: 15145509 Review.

8

Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.

Chester JD, Joel SP, Cheeseman SL, Hall GD, Braun MS, Perry J, Davis T, Button CJ, Seymour MT. Chester JD, et al. Among authors: hall gd. J Clin Oncol. 2003 Mar 15;21(6):1125-32. doi: 10.1200/JCO.2003.08.049. J Clin Oncol. 2003. PMID: 12637480 Clinical Trial.

9

A biofunctional review of C-reactive protein (CRP) as a mediator of inflammatory and immune responses: differentiating pentameric and modified CRP isoform effects.

Olson ME, Hornick MG, Stefanski A, Albanna HR, Gjoni A, Hall GD, Hart PC, Rajab IM, Potempa LA. Olson ME, et al. Among authors: hall gd. Front Immunol. 2023 Sep 15;14:1264383. doi: 10.3389/fimmu.2023.1264383. eCollection 2023. Front Immunol. 2023. PMID: 37781355 Free PMC article. Review.

10

Patient Outcomes Based on the 2011 CDC Guidelines for Field Triage of Injured Patients.

Fernandez AR, Bourn SS, Hall GD, Crowe RP, Myers JB. Fernandez AR, et al. Among authors: hall gd. J Trauma Nurs. 2023 Jan-Feb 01;30(1):5-13. doi: 10.1097/JTN.0000000000000691. J Trauma Nurs. 2023. PMID: 36633338

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

49 results

Search Page